Literature DB >> 17961813

[Improvement in the management of acute diarrhoea in France?].

A Martinot1, I Pruvost, M Aurel, V Hue, F Dubos.   

Abstract

The management of acute diarrhoea in France improved during the last ten years, with a large increase of oral rehydration solution (ORS) prescription in infants. Severity assessment is too often based on an uncertain evaluation of weight loss instead of a clinical determination. Telephone triage is not accurate without use of protocols and decision-making guidelines. Laboratory tests are rare in ambulatory management but still too frequent in hospital management of children with oral rehydration. ORS prescription of general practitioners regularly increased: 16% in 1988, 29% in 1996, 39% in 2001; and 71% in 2005 (after their reimbursement). The quality of oral rehydration advice remains insufficient. Intravenous rehydration on admission remains still too frequent. Drugs prescriptions include 2 or 3 drugs, with a decrease of loperamide and antibiotics, and an increase of racecadotril (81%). Lactose-free milk prescriptions in infants dropped from 46% in 1996 to 16% in 2005. Isolation and disinfection procedures are insufficient. Rotavirus nosocomial infections incidence is high: 1,6 to 6,3/1000 children less than 5 years of age, contributing to high direct costs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17961813     DOI: 10.1016/s0929-693x(07)80025-x

Source DB:  PubMed          Journal:  Arch Pediatr        ISSN: 0929-693X            Impact factor:   1.180


  1 in total

1.  Retrospective study of irrational prescribing in French paediatric hospital: prevalence of inappropriate prescription detected by Pediatrics: Omission of Prescription and Inappropriate prescription (POPI) in the emergency unit and in the ambulatory setting.

Authors:  Aurore Berthe-Aucejo; Phuong Khanh Hoang Nguyen; François Angoulvant; Xavier Bellettre; Patrick Albaret; Thomas Weil; Rym Boulkedid; Olivier Bourdon; Sonia Prot-Labarthe
Journal:  BMJ Open       Date:  2019-03-20       Impact factor: 2.692

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.